- Home
- NRSN vs CGTX Comparison
NRSN vs CGTX Comparison
Compare NRSN & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRSN
- CGTX
- Stock Information
- Founded
- NRSN 2017
- CGTX 2007
- Country
- NRSN Israel
- CGTX United States
- Employees
- NRSN N/A
- CGTX N/A
- Industry
- NRSN Biotechnology: Pharmaceutical Preparations
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- NRSN Health Care
- CGTX Health Care
- Exchange
- NRSN Nasdaq
- CGTX Nasdaq
- Market Cap
- NRSN 50.1M
- CGTX 53.4M
- IPO Year
- NRSN 2021
- CGTX 2021
- Fundamental
- Price
- NRSN $1.06
- CGTX $2.43
- Analyst Decision
- NRSN Buy
- CGTX Strong Buy
- Analyst Count
- NRSN 2
- CGTX 3
- Target Price
- NRSN $14.00
- CGTX $2.83
- AVG Volume (30 Days)
- NRSN 353.2K
- CGTX 11.9M
- Earning Date
- NRSN 09-29-2025
- CGTX 08-07-2025
- Dividend Yield
- NRSN N/A
- CGTX N/A
- EPS Growth
- NRSN N/A
- CGTX N/A
- EPS
- NRSN N/A
- CGTX N/A
- Revenue
- NRSN N/A
- CGTX N/A
- Revenue This Year
- NRSN N/A
- CGTX N/A
- Revenue Next Year
- NRSN N/A
- CGTX N/A
- P/E Ratio
- NRSN N/A
- CGTX N/A
- Revenue Growth
- NRSN N/A
- CGTX N/A
- 52 Week Low
- NRSN $0.68
- CGTX $0.22
- 52 Week High
- NRSN $2.60
- CGTX $3.83
- Technical
- Relative Strength Index (RSI)
- NRSN 33.59
- CGTX 63.80
- Support Level
- NRSN $1.05
- CGTX $2.62
- Resistance Level
- NRSN $1.17
- CGTX $3.83
- Average True Range (ATR)
- NRSN 0.12
- CGTX 0.45
- MACD
- NRSN 0.01
- CGTX 0.08
- Stochastic Oscillator
- NRSN 10.00
- CGTX 53.29
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.